NASH AWARE

Raising awareness for NASH, the silent killer liver disease.

Please follow and help spread the word!

[NASH AWARE @NASH_AWARE]

https://t.co/hhc32mPqmb

[NASH AWARE @NASH_AWARE]

AI is starting to show up in MASH clinical trials, liver imaging, and risk screening. It won’t solve everything, but if used well, it could help catch more patients earlier instead of letting liver disease stay hidden until it gets worse.

https://t.co/xwoRUOS2Pj

[NASH AWARE @NASH_AWARE]

My interview with @livrdiseasenews

https://t.co/OI9Z51AFeh

[NASH AWARE @NASH_AWARE]

Amazing evening at the legendary Arizona Biltmore for the ALF Flavors fundraiser! @liverUSA

[NASH AWARE @NASH_AWARE]

Fatty liver disease is common. So why are we still catching it so late?

We already have better tools to identify people at risk, but too many patients are still being missed until it's too late.

Why screening and follow-through need to improve.
https://t.co/k1cSCJhFhM

[American Liver Foundation National @liverUSA]

American Liver Foundation welcomes David Frank as new Chair of the Board.

Since first getting involved in 2014 after the loss of his mother to MASH, David has been a passionate advocate and leader in the liver disease community.

We also thank outgoing Chair Emmanuel Thomas, MD, PhD, FAASLD for his leadership in advancing research, partnerships, and innovation across ALF.

👉 Read more: https://t.co/gOz7odZeGx

#ALF50 #LiverHealth #HealthcareLeadership #NonprofitLeadership #LiverDisease

[NASH AWARE @NASH_AWARE]

I’ve been saying this for years: you can’t fix what you don’t measure.

Now, the federal government is finally paying attention to NAFLD/NASH. AHRQ released the first ever report on prevalence of this silent killer disease.

This is a turning point.

https://t.co/BtIaTykWpM

[NASH AWARE @NASH_AWARE]

Amazing @devex #UNGA side event on MASLD/MASH and how to raise awareness of this global NCD threat. Proud to represent the American Liver Foundation @liverUSA

[NASH AWARE @NASH_AWARE]

The FDA just approved Wegovy for MASH—the 2nd ever treatment for this silent killer liver disease and the first one with significant capabilities for widespread adoption. This is a huge development for liver patients everywhere!
https://t.co/z2nuuPYE9i

[NASH AWARE @NASH_AWARE]

Enormously positive news!

[American Liver Foundation National @liverUSA]

Important news: The @FDA has granted accelerated approval for @novonordisk's #Wegovy to treat metabolic dysfunction-associated steatohepatitis (MASH). This marks the 1st GLP-1 therapy approved for #MASH, offering new hope to patients & families. 🧵(1/2)
https://t.co/kYNzp3xAhz

[NASH AWARE @NASH_AWARE]

Amazing interview with the always great Gene Cautillo on @onnewjersey talking about the American Liver Foundations June 8th Liver Life Walk in Verona Park, NJ!

@liverUSA

https://t.co/wcskfGiKXF

[David Frank Writes @David_N_Frank]

@FoxNews @DrJBhattacharya @peta @DrJBhattacharya loved your comment on the rise of chronic disease...we had funding to AHRQ last year for the first Congressionally funded study on NAFLD/NASH. Over 90 million American's are estimated to have some form of this disease and we need more attention from NIH!

[NASH AWARE @NASH_AWARE]

I was proud today to represent the American Liver Foundation at the 2025 Liver Life Advocacy Summit in Washington D.C.

Dozens of advocates met with members of Congress and their staff to advance the ALF mission in a beautiful spring day.

NJ Strong!

@liverUSA

[American Liver Foundation National @liverUSA]

ALF is proud to have presented @RepJerryNadler (D-NY) with the foundation’s Congressional Champion Award for his dedication to advancing living donor transplantation and protecting living donors through the Living Donor Protection Act. #advocacy #LDLT #donatelife #livingdonor

[American Liver Foundation National @liverUSA]

Our AMAZING advocates are gathered in DC for the 2025 Liver Life Advocacy Summit to meet with their legislators and fight for the 100 million Americans affected by #liverdisease.💙💚 #advocacy #hillday

[NASH AWARE @NASH_AWARE]

At a recent UNGA sidelines event, many prominent health policy experts had never ever heard of NAFLD/NASH.

How is it that our healthcare system is failing so badly to address this issue? And what can we do? https://t.co/9P0B0KYiCL

[NASH AWARE @NASH_AWARE]

@AgrawalNina https://t.co/IZeMsEHHQq

[NASH AWARE @NASH_AWARE]

Good article from @AgrawalNina!

Years ago I asked a room full of Hepatologist's what the most effective treatment for NAFLD/NASH was and they unanimously said surgeries like this.

That's shifting today, because now GLP-1 drugs are changing the game.

https://t.co/0IkdHE2Pza

[NASH AWARE @NASH_AWARE]

Fantastic news for NASH patients.

[Alex Kesin @alexkesin]

This is really big news for MASH!

Akero Therapeutics' FGF21 agonist efruxifermin just demonstrated impressive efficacy in treating fatty liver disease. Around 1/3 of late stage (F4) patients even saw reversal of cirrhosis pathology over 3 years

[NASH AWARE @NASH_AWARE]

At a recent UNGA sidelines event, many prominent health policy experts had never ever heard of NAFLD/NASH.

How is it that our healthcare system is failing so badly to address this issue? And what can we do? https://t.co/9P0B0KYiCL

[NASH AWARE @NASH_AWARE]

Mom passed away 10 years ago this month only 6 weeks after being diagnosed with NASH.

I have been working ever since to raise awareness of this silent killer disease.

Her story is the lede of this NYT article on fatty liver disease.

https://t.co/2rhrxGRtmG